Vaccines for covid-19 patients

As part of the COVID-NMA initiative, we are identifying all randomized controlled trials (RCTs) of COVID-19 vaccine.

Below, you can access

Of note: For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.

We present the risk of Bias for phase 1-2 studies assessed for safety outcomes only.

Treatment comparisons

We report below the forest plots for the main treatment comparisons.

Please choose a Treatment Comparison:

Press releases

We acknowledged the publication of press release on the findings of the Novavax vaccine: COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial ">Novavax vaccine We will summarize and assess the study results once the full study reports have been published.

Last update: 16/04/2021

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04368988
Novavax
Keech C, N Engl J Med, 2020

Full text
Commentary
Non replicating viral vector

25mcg NVX-D0/21

5mcg NVX/M1-D0/21

25mcg NVX/M1-D0/21

25mcg NVX/M1+Placebo-D0/2

Placebo

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

NCT04530396
Gamaleya Research Institute of Epidemiology and Microbiology
Logunov D, Lancet, 2021
RESIST

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

Gam-COVID-Vac rAd26-S/rAd

Placebo

RCT
Phase 3
SARS-CoV-2- and HIV infection-free adult volunteers at 25 centers in Russia N=21977
Some concerns
Details

Full description

NCT04444674
University of Oxford/AstraZeneca
Madhi S, N Engl J Med, 2021
COV005
Updated

Full text
Commentary
Non replicating viral vector

ChAdOx1 5X10^10vp D0/D28

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026 N/A

Full description

NCT04436276
Janssen Pharmaceutical Companies
Sadoff J, N Engl J Med, 2021

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S 5x10^10vp

Ad26.COV2.S 1x10^11vp

Placebo

RCT
Phase 1-2
Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US N=810
Some concerns
Details

Full description

ISRCTN89951424
University of Oxford/AstraZeneca
Voysey M, Lancet, 2020
COV003
Updated

Full text
Commentary
Non replicating viral vector

ChAdOx1 SD/SD

MenACWY/saline

RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=10002
Some concerns
Details

Full description

NCT04400838
University of Oxford/AstraZeneca
Voysey M, Lancet, 2020
COV002
Updated

Full text
Commentary
Non replicating viral vector

ChAdOx1 LD/SD

ChAdOx1 SD/SD

MenACWY

RCT
Phase 2/3
Healthy adults in 18 centres in the UK N=10673
Some concerns
Details

Full description

NCT04324606 / EudraC
University of Oxford/AstraZeneca
Voysey M, Lancet, 2021
COV001/COV002/COV003/COV005

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

ChAdOx1

MenACWY/saline

RCT
phase 1/2/3
Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK N=24422
Some concerns
Details

Full description

NCT04341389
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F, Lancet, 2020

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-vectored 1×10¹¹ vp

Ad5-vectored 1×10¹¹ vp

Ad5-vectored 5×10¹⁰ vp

Ad5-vectored 5×10¹⁰ vp

Placebo

Placebo

RCT
Phase 2
Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description

The link in the column "Overall risk of bias" provides access to a complete description of the assessment of each risk of bias domain with supports for judgement produced using the Revised Cochrane risk-of-bias tool for randomized trials RoB 2.

The risk of bias by domain as well as overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review. The link in the column "Full description" provides access to the general characteristics of the study.

We acknowledge that we may have been unable to extract some information from pre-prints, as they represent preliminary forms of scientific communication.